A new study found a negative correlation between salivary rates and disease severity for patients with psoriasis.

Focusing on the role of eosinophils in diagnosing COPD, the panel discusses how often they should be tested, the cut-off value, and the natural changes of eosinophils in the disease course.

Using available literature, the review assesses our current understanding of AATD, emerging biomarkers, and the future of drug development.

The panel discusses unmet needs in the COPD treatment landscape, highlights the shortcomings of current treatment strategies, and provides insights on diagnostic practices.

Paul E. Sax, MD, and Sorana Segal-Maurer, MD, discuss treatment resistance in HIV and how it has changed over the years.

The panel discusses the importance of starting HIV treatment early after diagnosis and offers advice to clinical providers.

A similar proportion of patients sustained baseline clinical status across treatment arms.

The FDA will decide on an application this summer for the treatment of PTSD with MDMA-assisted therapy. A renowned researcher explains how the treatment benefits patients with trauma.

At APA 2024, psychiatry experts shared their message to their colleagues for Mental Health Awareness Month.

Results from a Phase I trial showed significant LDL-C reduction with AZD0780 plus statin therapy in treatment-naive patients with hypercholesterolemia.

A new study found patients with psoriasis and depression have increased levels of C-reaction proteins and the erythrocyte sedimentation rate.

The case-control study found the prevalence of MASLD was greater among patients with plaque psoriasis, further suggesting a potential synergistic role between the two.

The FDA moved the target date for their decision on the dupilumab application by 3 months, citing a need for more efficacy data from its pivotal phase 3 trials.

Statistically significant higher proportions of patients with CD or UC receiving subcutaneous CT-P13 achieved clinical remission compared with placebo.

At ARVO 2024, Dimitra Skondra, MD, describes the association between metformin use and decreased new-onset ICD coding of GA.

The analysis of NHANES data revealed a dose-response association between weekly moderate-to-vigorous physical activity levels and hyperuricemia risk.

At week 54, the clinical remission rate among patients receiving originator infliximab was 92.5% compared with 100% in the biosimilar CT-P13 group.

The new psychedelic CPT codes, effective January 1, 2024, could impact MDMA if approved. The FDA's Psychopharmacologic Drugs Advisory Committee will discuss MDMA on June 4.

New phase 2 trial data show more than double the patients receiving daily STS-01 1% cream achieved ≥30% improvement in SALT scores.

Announced on May 29, 2024, data from the MDD3001 trial indicate use of seltorexant was associated with meaningful improvements in depressive symptoms and sleep disturbances.

Anjali Tiku Owens, MD, examines mavacamten, the pioneering cardio myosin inhibitor (CMI) approved for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), which is exclusively accessible through the restricted Risk Evaluation and Mitigation Strategy (REMS) program; the KOL delves into the objectives of this program and how it strives to enhance medication safety and optimize patient outcomes.

Anjali Tiku Owens, MD, explores the role of cardiac myosin inhibitors in the treatment strategies for patients with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with the latest European Society of Cardiology (ESC) Guidelines released in 2023.

Blocking IL-33 production with statins may be an effective preventive strategy to suppress chronic inflammation and the development of certain cancers.

Patients with AATD-associated lung disease on augmentation therapy participating in a health management program experienced negligible changes in self-perceived health status.

Robert Rosenson, MD, discusses the results of the ARCHES-2 trial and how it informs the potential of ANGPTL3 inhibition as well as RNAi therapies.